Neuroblastoma
Malignant Embryonal Tumor of the Sympathetic Nervous System
Primary risk age: Infants and toddlers (Median age of diagnosis is 19 months; most common solid extracranial tumor in children)
- Urgency
- Severe
- Typical age
- Infants and toddlers (Median age of diagnosis is 19 months; most common solid extracranial tumor in children)
- Body system
- Oncological System
Typical course: Low-risk surgery recovery takes weeks; high-risk multi-modality therapy spans 12 to 18 months.
Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13
1. Summary & Pathophysiology
Malignant Embryonal Tumor of the Sympathetic Nervous System
Pathophysiology (Development Path)
Abnormal differentiation and migration of neural crest cells during fetal development. These immature sympathetic cells fail to mature and instead undergo malignant clonal expansion, forming a tumor anywhere along the sympathetic chain (most commonly in the adrenal medulla). Tumor cells secrete catecholamines.
Primary Causes & Etiology
Primarily idiopathic embryonal origin; arising from primordial neural crest cells. Associated with mutations in the ALK gene in rare familial cases.
2. Symptom Continuum
- Early Onset Signs
Vague symptoms depending on tumor location: mild abdominal discomfort, poor appetite, and low-grade fever.
- Progressive Phase
A firm, irregular, painless abdominal mass that crosses the midline (adrenal tumor). Hypertension (due to catecholamine release or renal artery compression) and diarrhea.
- Severe Indicators
Metastatic disease signs: "raccoon eyes" (periorbital bruising/ecchymosis due to orbital bone metastasis), bone pain, bone marrow suppression (anemia, bruising), and "blueberry muffin" skin lesions in infants.
3. Clinical Verification
Elevated urinary catecholamine metabolites (HVA and VMA). Confirmed by tumor biopsy showing small, round, blue cells. MIBG scan to map metastatic bone lesions. Genetic evaluation showing MYCN amplification (predicts aggressive disease).
4. Care & Elements Plan
Primary Care Treatment Plan
Risk-stratified approach. Low-risk tumors (especially in infants $<18$ months) may require surgery only or even undergo spontaneous regression. High-risk disease requires multi-agent chemotherapy, surgical resection, autologous stem cell transplant, radiation, and immunotherapy.
Home Support Elements
Support nutrition during aggressive chemotherapy. Monitor blood counts and check for fevers. Provide gentle skin care and manage pain.
Generic Active Ingredients (No Brands)
- Cyclophosphamide or Cisplatin (generic active alkylating/platinum chemotherapy agents)
- Doxorubicin (generic active anthracycline chemotherapy)
- Dinutuximab (active immunotherapy monoclonal antibody).
Lists active elements only. Never administer self-designed therapies.
5. Doctor Critical Lines
Critical Thresholds: When to See a Doctor
Consult a pediatrician if you feel a hard lump in your child's abdomen, or if they develop unexplained bruising around their eyes or refuse to walk due to bone pain.
6. Vaccine & Prevention
Routine Prophylaxis (Prevention)
No preventative measures exist, as this is an embryonal developmental tumor.
Immunization Context
Avoid live vaccines during active immunosuppressive oncology treatments.
7. Timelines & Outlook
Active Timeline
Low-risk surgery recovery takes weeks; high-risk multi-modality therapy spans 12 to 18 months.
Expected Prognosis
Excellent for low- and intermediate-risk disease (survival $>90%$). High-risk disease (especially with MYCN amplification) has a guarded prognosis, with survival around 50% despite intensive therapy.
Potential Untreated Complications
Metastasis, spinal cord compression (from tumor extending into the spinal canal), hearing loss (from cisplatin), and renal impairment.
